Genelux Corp Files 8-K Report

Ticker: GNLX · Form: 8-K · Filed: Aug 1, 2024 · CIK: 1231457

Genelux Corp 8-K Filing Summary
FieldDetail
CompanyGenelux Corp (GNLX)
Form Type8-K
Filed DateAug 1, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, regulation-fd

TL;DR

GENELUX filed an 8-K on Aug 1, 2024, expect updates.

AI Summary

On August 1, 2024, Genelux Corporation filed an 8-K report to disclose information under Regulation FD and to file financial statements and exhibits. The company, incorporated in Delaware, is based in Westlake Village, California, and operates in the Pharmaceutical Preparations industry. This filing serves as a current report detailing significant events or information relevant to investors.

Why It Matters

This 8-K filing indicates that Genelux Corporation is providing updated information to the public, which could include material events or financial disclosures relevant to its current business operations and investor relations.

Risk Assessment

Risk Level: low — This filing is a standard 8-K current report, typically used for routine disclosures and does not inherently signal significant risk.

Key Numbers

  • 001-41599 — Commission File Number (Identifies the company's filing with the SEC)
  • 77-0583529 — I.R.S. Employer Identification No. (Company's tax identification number)

Key Players & Entities

  • Genelux Corporation (company) — Registrant
  • August 1, 2024 (date) — Date of earliest event reported
  • Delaware (jurisdiction) — State of incorporation
  • Westlake Village, California (location) — Principal executive offices
  • 2625 Townsgate Road, Suite 230 (address) — Principal executive offices address

FAQ

What specific information is being disclosed under Regulation FD in this 8-K filing?

The provided text does not specify the exact content disclosed under Regulation FD, only that it is a category of disclosure for this filing.

Are there any financial statements included with this 8-K filing?

Yes, the filing explicitly states 'Financial Statements and Exhibits' as an item information, indicating their inclusion.

What is Genelux Corporation's primary business sector?

Genelux Corporation is listed under the Standard Industrial Classification code 2834, which corresponds to 'Pharmaceutical Preparations'.

When was the earliest event reported in this 8-K filing?

The earliest event reported is dated August 1, 2024.

What is the physical address of Genelux Corporation's principal executive offices?

The principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California, 91361.

Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-08-01 09:00:56

Key Financial Figures

  • $0.001 — ch registered Common stock, par value $0.001 per share GNLX The Nasdaq Stock Mar

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Genelux Corporation Date: August 1, 2024 By: /s/ Thomas Zindrick, J.D. Thomas Zindrick, J.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.